Alterity Therapeutics price target raised to $12 from $8 at Maxim
Maxim analyst Jason McCarthy raised the firm’s price target on Alterity Therapeutics (ATHE) to $12 from $8 and keeps a Buy rating on the shares ...
CurePSP Furthers Investment in Collaborative Research on Care of Rare Neurological Diseases
CurePSP announced the recipients of their Collaborative Approaches to Resources, Education and Support (CARES) grants designed to advance best practices in the care of progressive supranuclear palsy ...
What's Going On With Alterity Therapeutics Shares Thursday?
Alterity Therapeutics shares are moving higher on Thursday after the company reported positive topline results from its Phase 2 clinical trial of ATH434 in early-stage multiple system atrophy.
Hosted on MSN19h
Alterity Therapeutics Stock Doubles Premarket On Positive MSA Trial Results: Retail Excitement Soars
Shares of Alterity Therapeutics soared 108% premarket Thursday, surging toward levels last seen in September 2022, with trading volume nearly 75 times the daily average. The clinical-stage biotech ...
Alterity Therapeutics announces ATH434 Phase 2 trial results
Alterity Therapeutics (ATHE) announced topline results from the ATH434-201 randomized, double-blind, placebo-controlled Phase 2 clinical trial ...
Alterity surges after mid-stage trial data for lead asset
Alterity Therapeutics (ATHE) stock jumps as its lead asset, ATH434, shows promise in slowing clinical progression in multiple ...